Psychedelic and ketamine research trials in Argentina

Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.

5 registered studies are counted in Argentina. By compound: 1 psilocybin, 2 DMT, 2 5-MeO-DMT and 2 ketamine. By registry status: 5 completed. By phase: 2 phase 1, 1 phase 3, 1 phase 4 and 1 not applicable. Reported start years run from 2020 (earliest) to 2024 (latest). Studies are linked to 4 institutions.

Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

Recruiting now

None of the 5 counted studies in Argentina is listed in the registry as recruiting or not yet recruiting as of 11 October 2026. Status is reported by study teams and can be out of date.

At a glance

5 registered studies are counted on this page.

By compound

Compound hub	Studies
Psilocybin	1
DMT	2
5-MeO-DMT	2
Ketamine	2

By registry status

Status	Studies	Share
Completed	5	100%

By phase

Phase	Studies	Share
Phase 1	2	40%
Phase 3	1	20%
Phase 4	1	20%
Not applicable	1	20%

When studies started

Start year	Studies
2024 to 2026	2
2020 to 2023	3

All counted studies

All 5 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registered	Registry ID	Status	Phase	Start	Institution and city
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI	NCT06812221	Completed	Phase 1	2024-12-15	Biomind Labs Inc., San Juan
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety	NCT06816667	Completed	Phase 1	2024-10-21	Biomind Labs Inc., San Juan
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment	NCT04829318	Completed	Phase 4	2021-04-26	Janssen-Cilag Ltd., Buenos Aires
Naturalistic Study of Microdosing With Psilocybin	NCT05160220	Completed	Not applicable	2021-01-20	National Council of Scientific and Technical Research, Argentina, Buenos Aires
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder	NCT04338321	Completed	Phase 3	2020-08-21	Janssen-Cilag International NV, Buenos Aires

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Psilocybin | DMT | 5-MeO-DMT | Ketamine

Condition hubs

Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.

Condition hub	Studies in this country
Depression	4
Anxiety	2
Treatment-resistant depression	2

Other country hubs

All trial hubs | Learn | Disclaimer